Paul Petrakos, DO
Glaucoma Specialist · New York, NYNPI 1134545171
Payments from drug & device makers
What this record shows
Bausch & Lomb Americas Inc. accounts for 67.5% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $1,893, 6.0 times the $316 reported in 2019. That places this record below the midpoint for glaucoma specialist clinicians in NY, where the typical reported total is $2,507.
Across 21 payments — averaging $124.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$2K
- AbbVie$329
- Glaukos Corporation$271
- Sight Sciences, Inc.$118
- NEW World Medical,inc.$96
- Sun Pharmaceutical Industries Inc.$24
- plus $15 from 1 others
What the payments were for
- Travel & lodging$1,42954%
- Food & beverage$1,19546%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 10 | $1,771 |
| AbbVie(2 entities) | 4 | $329 |
| Glaukos Corporation | 3 | $271 |
| Sight Sciences, Inc. | 1 | $118 |
| NEW World Medical,inc. | 1 | $96 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Alcon | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,624 in reported general payments places this provider in the 50th percentile of 35 glaucoma specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 118 | $76,935 |
| RestasisCyclosporine | 94 | $71,558 |
| RocklatanNetarsudil Mesylat/Latanoprost | 134 | $70,799 |
| CombiganBrimonidine Tartrate/Timolol | 102 | $41,264 |
| XiidraLifitegrast | 27 | $39,000 |
| RhopressaNetarsudil Mesylate | 27 | $21,572 |
| Alphagan PBrimonidine Tartrate | 39 | $19,184 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 94 | $16,962 |
| VyzultaLatanoprostene Bunod | 33 | $16,665 |
| Brimonidine Tartrate | 247 | $15,722 |
| Cyclosporine | 21 | $9,257 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 28 | $8,747 |
| Travoprost | 52 | $8,580 |
| Prednisolone Acetate | 183 | $8,493 |
| Latanoprost | 814 | $8,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $329 | $208,941353 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,771 | $55,66460 claims |
| AlconSimbrinza, Azopt | $15 | $13,23240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 35 glaucoma specialist providers in New York.
Other glaucoma specialist in New York
- Janet SerleNew York$103K
- Sarah VantasselNew York$76K
- Sonya DharNew York$19K
- Yvonne OkakaNew York$5K
- Varun ReddyNew York$4K
- Eileen ChangNew York$3K
- Gerald SheppsNew York$3K
- Nehali NantiNew York$2K
- Johnny LiNew York$2K
- Louis PasqualeNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.